The effect of Glycyrrhiza glabra vaginal cream on treatment of vaginal atrophy of postmenopausal women

Comparison the effect of Glycyrrhiza glabra and placebo vaginal creams on treatment of vaginal atrophy in postmenopausal women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017010331739N1

Enrollment

Registered

2017-01-27

Start date

2017-01-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal atrophy. Postmenopausal Atrophic Vaginitis

Interventions

Intervention 1: Subjects in intervention group will receive one time in each night Glycyrrhiza glabra vaginal cream 2% using an applicator for 8 weeks. Intervention 2: Subjects in control group will r

Treatment - Drugs

Subjects in intervention group will receive one time in each night Glycyrrhiza glabra vaginal cream 2% using an applicator for 8 weeks.

Subjects in control group will receive one time in each night placebo vaginal cream using an applicator for 8 weeks.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women with sexual activity and single partner; passing at least 12 months of amenorrhea; presence of vaginal atrophy symptoms; normal blood pressure. Exclusion criteria: Genital abnormalities; breast diseases with unknown reason; liver cholestatic disorders; renal failure; vaginal infection needing treatment; genital bleeding or spotting with unknown reason; hormone therapy or using sex hormones within the 2 months before the study; using of phytoestrogens such as soy, red clover, fenugreek, and vitex within the last one month; body mass index more than 30 kilogram per cubic meter. .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Vaginal acidity. Timepoint: Before and after intervention. Method of measurement: By PH strip.;Subjectiv symptoms of vaginal atrophy. Timepoint: Before intervention and two, four and eight weeks after the intervention. Method of measurement: Kupperman index questionnaire.;Dyspareunia. Timepoint: Before intervention and two, four and eight weeks after the intervention. Method of measurement: Dyspareunia self-administered scale.;Vaginal dryness. Timepoint: Before intervention and two, four and eight weeks after the intervention. Method of measurement: Vaginal dryness self-administer scale.;Percent of vaginal cells maturation. Timepoint: Before and after intervention. Method of measurement: Vaginal smear.	—

Measure

Time frame

Vaginal acidity. Timepoint: Before and after intervention. Method of measurement: By PH strip.;Subjectiv symptoms of vaginal atrophy. Timepoint: Before intervention and two, four and eight weeks after the intervention. Method of measurement: Kupperman index questionnaire.;Dyspareunia. Timepoint: Before intervention and two, four and eight weeks after the intervention. Method of measurement: Dyspareunia self-administered scale.;Vaginal dryness. Timepoint: Before intervention and two, four and eight weeks after the intervention. Method of measurement: Vaginal dryness self-administer scale.;Percent of vaginal cells maturation. Timepoint: Before and after intervention. Method of measurement: Vaginal smear.

—

Secondary

Measure	Time frame
Sexual function. Timepoint: Before and after intervention. Method of measurement: Female sexual function index questionnaire.;Sexual satisfaction. Timepoint: Before and after intervention. Method of measurement: Larson's sexual satisfaction questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactahra Abbaspoor

Ahvaz Jundishapur University of Medical Sciences

Abbaspoor-z762@yahoo.com+98 61 3373 8331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026